The implant is less invasive and quick to insert. It involves fixing two adjacent vertebra by compression around a previously-inserted interbody cage.
“Following an examination of the product’s clinical data — almost 5,000 units have already been implanted outside the United States since the product’s launch in 2006 — the FDA has approved our cervical staple in the US market for the same indications as cervical plates. This approval has given rise to the creation of a new product code in the FDA’s internal classification, giving the product a unique position on the spinal column fixation device market,” said Denys Sournac, chairman and CEO of MEDICREA.
More Articles on Devices:
Revenue up 3%, new strategy revealed: 10 key notes from Smith & Nephew’s 2Q financial report
Smith & Nephew to move some production to China
K2M’s new spine system launches, clearances: 3 updates
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
